Trial results

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

NCT07794579 on ClinicalTrials.gov · last registry update 2026-08-31

An unusually large phase 3: 2,001 participants, more than double the 424 typical for the stage. Due to report August 2029, alongside 12 other tracked readouts that quarter. Primary outcome, as filed: Time to Onset of Obesity Related Complications or Class 1 Obesity. Sponsors move these dates routinely; any movement since this site started watching is listed below. orforglipron is approved in the US, but not for hypertension and prediabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it. The registry entry has been edited 1 time since then.

Status

NOT_YET_RECRUITING

Phase

P3

Drug

orforglipron

Foundayo

Sponsor

Eli Lilly and Company

Sponsor type

Industry

Enrollment

2,001

Started

2026-09

Primary completion

2029-08 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Time to Onset of Obesity Related Complications or Class 1 Obesity

Conditions studied

Overweight · Prediabetic State · Prehypertension · Obesity, Abdominal

Every field above is taken directly from the registry record. See all detected changes across the class, or the orforglipron page for this molecule’s full trial and approval history.